Caxton Associates (New York)’s Bio-Techne TECH Stock Holding History

Caxton Associates (New York)’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,532	Closed	-$930K	–	648
2023 Q1	$930K	Buy	+12,532	New	+$966K	0.14%	158
2022 Q4	–	Sell	-3,012	Closed	-$214K	–	605
2022 Q3	$214K	Buy	+3,012	New	+$260K	0.03%	388
2022 Q1	–	Sell	-4,312	Closed	-$558K	–	698
2021 Q4	$558K	Buy	+4,312	New	+$529K	0.06%	254
2019 Q3	–	Sell	-8,692	Closed	-$453K	–	539
2019 Q2	$453K	Hold	8,692	–	–	0.05%	210
2019 Q1	$431K	Buy	+8,692	New	+$391K	0.06%	173

Other funds holding TECH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DDC

DF Dent & Co Baltimore, Maryland $5.27B AUM 7.89% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Caxton Associates (New York)'s TECH Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Bio-Techne (TECH) in Q2 2023, closing a stake of 12,532 shares — an estimated $930K sold.

Caxton Associates (New York) first reported a position in TECH in Q1 2019 and held it in 5 quarters. The position peaked at $930K in Q1 2023. 529 funds tracked by Wall St. Rank hold TECH as of Q2 2023.

Caxton Associates (New York) reported no remaining Bio-Techne position as of Q2 2023 after selling out during the quarter.
Caxton Associates (New York) sold 12,532 Bio-Techne shares in Q2 2023, an estimated $930K.
Caxton Associates (New York) first reported a position in Bio-Techne in Q1 2019 and held it in 5 quarters.
Caxton Associates (New York)'s Bio-Techne position peaked at $930K in Q1 2023.
529 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.